Combining chemotherapy with a BRAF oncogene inhibitor proves effective at treating this disease in a mouse model. This alternative paves the way toward a new approach for patients affected by this type of tumor, which has no cure in the most advanced stages or cases of relapse.
Scientists reveal that during hematopoietic regeneration, RNA expressed from a part of the genome considered ‘junk DNA’ is used by hematopoietic stem cells to get activated and proliferate. The study shows that these so-called transposable elements make RNA after chemotherapy and activate an immune receptor which induces inflammatory signals enhancing hematopoietic stem cell cycling and thus participating in the regeneration of the hematopoietic system.
A new treatment has potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a PARP inhibitor has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Chemotherapy destroys stem cells, which then cannot develop into immune cells and become part of the body’s defenses. There are drugs that can remedy this, but previously we did not know exactly how these drugs worked. Now, a new study details their function providing new knowledge that may improve stem cell transplantation and lead to better drug design in the future.
A new study found that specific types of gut bacteria can protect other good bacteria from cancer treatments — mitigating harmful, drug-induced changes to the gut microbiome. By metabolizing chemotherapy drugs, the protective bacteria could temper short- and long-term side effects of treatment.
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy.
University of Minnesota Medical School researchers revealed why some glioblastoma patients see exceptional benefits from chemotherapy and survive beyond expectations.
An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study suggests that a minor adjustment to the current standard treatment — giving chemotherapy in the morning rather than the evening — could add a few months to patients’ survival.
Cancer cells can dodge chemotherapy by entering a state that bears similarity to certain kinds of senescence, a type of ‘active hibernation’ that enables them to weather the stress induced by aggressive treatments aimed at destroying them, according to a new study. These findings have implications for developing new drug combinations that could block senescence and make chemotherapy more effective.
Researchers demonstrated that a new tumor-penetrating therapy could enhance the effects of chemotherapy, reduce the spread of pancreatic cancer and increase survival in animal models.
A new substance could improve the treatment of persistent cancers. Researchers have developed a new inhibitor that makes drug-resistant tumor cells respond again to chemotherapy. The new substance blocks a protein in the cancer cells that normally transports the cancer drugs back out of the cells.
Cancer stem cells that elude conventional treatments like chemotherapy drive long-term cancer growth and relapse. These cells are difficult to isolate and study because of their low abundance and similarity to other stem cells. Researchers have created a new method that can distinguish cancer stem cells, mature cancer cells and otherwise healthy stem cells based on their genetics and gene expression. The findings open new avenues for cancer research personalised medicine.
Vascular and interventional radiologists report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors.
There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial.
Researchers show that cancer cells hijack an evolutionary conserved program to survive chemotherapy. Furthermore, the researchers show that novel therapeutic strategies aimed at specifically targeting cancer cells in this slow-dividing state can prevent cancer regrowth.
Women who take statins, the common cholesterol-lowering medication, during chemotherapy with anthracyclines for early-stage breast cancer are half as likely to require emergency department visits or hospitalization for heart failure in the 5 years after chemotherapy.
The study found that ‘loading’ a chemotherapy drug on to tiny magnetic particles that can heat up the cancer cells at the same time as delivering the drug to them was up to 34% more effective at destroying the cancer cells than the chemotherapy drug without added heat.
Surgery, in addition to treatments like chemotherapy and radiation therapy, may increase the length of survival for metastatic breast cancer patients, according to researchers.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer.
Current chemotherapy regimens slow cancer progression and save lives, but these powerful drugs affect both healthy and cancerous cells. Now, researchers have designed DNA-based nanogels that only break down and release their chemotherapeutic contents within cancer cells, minimizing the impacts on normal ones and potentially eliminating painful and uncomfortable side effects.
The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a new model. This research may make it possible to use genetic analysis to identify patients with a high probability of side effects.
Multidrug resistance (MDR) — a process in which tumors become resistant to multiple medicines — is the main cause of failure of cancer chemotherapy. Tumor cells often acquire MDR by boosting their production of proteins that pump drugs out of the cell, rendering the chemotherapies ineffective. Now, researchers have developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR.
Biologists reveal that tissue perturbations by chemotherapy agents promote stem cell expansion and that fibroblast cells exhibit unexpected, immune-like behavior.